Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters

Overview

Journal AAPS J

Specialty Pharmacology

Date 2005 Dec 16

PMID 16353950

Citations 10

Authors

Christopher K Surratt

Okechukwu T Ukairo

Suneetha Ramanujapuram

Affiliations

Soon will be listed here.

Abstract

The plasma membrane monoamine transporters terminate neurotransmission by removing dopamine, norepinephrine, or serotonin from the synaptic cleft between neurons. Specific inhibitors for these transporters, including the abused psychostimulants cocaine and amphetamine and the tricyclic and SSRI classes of antidepressants, exert their physiological effects by interfering with synaptic uptake and thus prolonging the actions of the monoamine. Pharmacological, biochemical, and immunological characterization of the many site-directed, chimeric, and deletion mutants generated for the plasma membrane monoamine transporters have revealed much about the commonalities and dissimilarities between transporter substrate, ion, and inhibitor binding sites. Mutations that alter the binding affinity or substrate uptake inhibition potency of inhibitors by at least 3-fold are the focus of this review. These findings are clarifying the picture regarding substrate uptake inhibitor/transporter protein interactions at the level of the drug pharmacophore and the amino acid residue, information necessary for rational design of novel medications for substance abuse and a variety of psychiatric disorders.

Citing Articles

Tryptophan and Substance Abuse: Mechanisms and Impact.

Davidson M, Rashidi N, Hossain M, Raza A, Nurgali K, Apostolopoulos V Int J Mol Sci. 2023; 24(3).

PMID: 36769059 PMC: 9917371. DOI: 10.3390/ijms24032737.

Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs.

Krout D, Pramod A, Dahal R, Tomlinson M, Sharma B, Foster J Biochem Pharmacol. 2017; 142:204-215.

PMID: 28734777 PMC: 8475752. DOI: 10.1016/j.bcp.2017.07.015.

Structure and Dynamics Study of LeuT Using the Markov State Model and Perturbation Response Scanning Reveals Distinct Ion Induced Conformational States.

Asciutto E, Gedeon P, General I, Madura J J Phys Chem B. 2016; 120(33):8361-8.

PMID: 27311999 PMC: 5675527. DOI: 10.1021/acs.jpcb.6b02053.

Classic Studies on the Interaction of Cocaine and the Dopamine Transporter.

Verma V Clin Psychopharmacol Neurosci. 2015; 13(3):227-38.

PMID: 26598579 PMC: 4662164. DOI: 10.9758/cpn.2015.13.3.227.

Structural dynamics of the monoamine transporter homolog LeuT from accelerated conformational sampling and channel analysis.

Thomas J, Gedeon P, Madura J Proteins. 2014; 82(10):2289-302.

PMID: 24753369 PMC: 4177338. DOI: 10.1002/prot.24588.

References

Kitayama S, Shimada S, Xu H, Markham L, Donovan D, Uhl G . Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A. 1992; 89(16):7782-5. PMC: 49795. DOI: 10.1073/pnas.89.16.7782. View

Pristupa Z, Wilson J, HOFFMAN B, Kish S, Niznik H . Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994; 45(1):125-35. View

Giros B, Wang Y, Suter S, McLeskey S, Pifl C, Caron M . Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem. 1994; 269(23):15985-8. View

Barker E, Kimmel H, Blakely R . Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol. 1994; 46(5):799-807. View

Lever J, Zou M, Parnas M, Duval R, Wirtz S, Justice J . Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible labeling of dopamine transporters: synthesis and covalent binding studies. Bioconjug Chem. 2005; 16(3):644-9. DOI: 10.1021/bc0497214. View

Spencer T, Biederman J, Madras B, Faraone S, Dougherty D, Bonab A . In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005; 57(11):1293-300. DOI: 10.1016/j.biopsych.2005.03.036. View

Chen R, Han D, Gu H . A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem. 2005; 94(2):352-9. DOI: 10.1111/j.1471-4159.2005.03199.x. View

Sutcliffe J, Delahanty R, Prasad H, McCauley J, Han Q, Jiang L . Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet. 2005; 77(2):265-79. PMC: 1224529. DOI: 10.1086/432648. View

Ukairo O, Bondi C, Newman A, Kulkarni S, Kozikowski A, Pan S . Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005; 314(2):575-83. DOI: 10.1124/jpet.105.085829. View

10.

Yamashita A, Singh S, Kawate T, Jin Y, Gouaux E . Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature. 2005; 437(7056):215-23. DOI: 10.1038/nature03978. View

11.

Lee S, Kang S, Son H, Lee Y . The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function. Biochem Biophys Res Commun. 1998; 246(2):347-52. DOI: 10.1006/bbrc.1998.8618. View

12.

Lee K, Kim M, Kim D, Lee Y . Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem Res. 2004; 29(7):1405-9. DOI: 10.1023/b:nere.0000026404.08779.43. View

13.

Fischer J, Cho A . Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979; 208(2):203-9. View

14.

Brandl C, Deber C . Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc Natl Acad Sci U S A. 1986; 83(4):917-21. PMC: 322981. DOI: 10.1073/pnas.83.4.917. View

15.

Eisenman G, Dani J . An introduction to molecular architecture and permeability of ion channels. Annu Rev Biophys Biophys Chem. 1987; 16:205-26. DOI: 10.1146/annurev.bb.16.060187.001225. View

16.

Strader C, Sigal I, Candelore M, Rands E, HILL W, Dixon R . Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem. 1988; 263(21):10267-71. View

17.

Smicun Y, Campbell S, Chen M, Gu H, Rudnick G . The role of external loop regions in serotonin transport. Loop scanning mutagenesis of the serotonin transporter external domain. J Biol Chem. 1999; 274(51):36058-64. DOI: 10.1074/jbc.274.51.36058. View

18.

Loland C, Norregaard L, Gether U . Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site. J Biol Chem. 1999; 274(52):36928-34. DOI: 10.1074/jbc.274.52.36928. View

19.

Dougherty D, Bonab A, Spencer T, Rauch S, Madras B, Fischman A . Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999; 354(9196):2132-3. DOI: 10.1016/S0140-6736(99)04030-1. View

20.

Saier Jr M . A functional-phylogenetic system for the classification of transport proteins. J Cell Biochem. 2000; Suppl 32-33:84-94. DOI: 10.1002/(sici)1097-4644(1999)75:32+<84::aid-jcb11>3.0.co;2-m. View